Fate Therapeutics, Inc. (FATE) vs Upstream Bio, Inc. (UPB)
Fate Therapeutics, Inc. and Upstream Bio, Inc. are both Biotechnology companies. Fate Therapeutics, Inc. and Upstream Bio, Inc. are of similar size ($283.2M and $279.2M). Upstream Bio, Inc. grew revenue faster over the last twelve months: 16.0% against −23.4%. Fate Therapeutics, Inc. has the higher net margin (−1,941.1% vs −4,955.7%) and the higher return on invested capital (0.00% vs −1,100.9%). Across the 15 metrics below, Fate Therapeutics, Inc. leads on 9 and Upstream Bio, Inc. on 6.
Valuation
Profitability
| Metric | FATE | UPB | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | (2,058.08%) | (5,382.65%) | 0.00% |
| Net margin | (1,941.09%) | (4,955.67%) | 0.00% |
| Free cash flow margin | (1,624.06%) | (4,317.42%) | 0.00% |
| Return on equity | (60.75%) | (46.05%) | (57.72%) |
| Return on assets | (39.89%) | (44.61%) | (49.22%) |
| Return on invested capital | 0.00% | (1,100.93%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack